NCT00479297View on ClinicalTrials.gov

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Alzheimer Disease
Interventions
DRUG

SAM-531

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00479297 - Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males | Biotech Hunter | Biotech Hunter